Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study
Cancers · 30.10.2026 · 18 (21) · 3497
DOI: 10.3390/cancers18213497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.10.2026. Verfasst von Clément Bolognini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Besançon University Hospital (CHU Jean Minjoz), 25000 Besançon, France. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Metronomic cyclophosphamide (MCP) is sometimes used for advanced soft-tissue sarcoma (STS) when standard therapies are unsuitable. We assessed its activity and safety in routine practice.
Methods
This French three-center retrospective study included 60 adults with unresectable or metastatic STS who started MCP in 2008–2021. Patients received oral cyclophosphamide 50 mg twice daily on days 1–7 of 14-day cycles; 12 (20%) also received prednisolone during treatment weeks. The primary endpoint was progression-free survival (PFS).
Results
Median age was 70 years; 55% had ECOG performance status 2–3. Median PFS and overall survival (OS) were 2.6 months (95% CI, 1.8–3.6) and 6.4 months (95% CI, 4.2–9.3), respectively. The objective response rate was 5.0% (3/60; exact 95% CI, 1.0–13.9%) and the disease control rate was 21.7% (13/60; exact 95% CI, 12.1–34.2%); ten patients (16.7%) were not radiologically evaluable. In 21 patients aged >65 years treated in the first- or second-line setting, median PFS and OS were 3.2 and 7.7 months. Treatment-related adverse events were documented in 16 patients (26.7%), with no grade ≥3 events recorded.
Conclusions
Intermittent low-dose MCP showed limited antitumor activity but favorable clinician-documented short-term tolerability in this multicenter cohort. Alongside prospective evidence, the results do not support routine use in unselected patients. MCP may retain an individualized palliative role when established systemic therapy is unsuitable.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Besançon University Hospital (CHU Jean Minjoz), 25000 Besançon, France.
- Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
- Methodology and Quality of Life in Oncology Unit, Besançon University Hospital, 25000 Besançon, France.
- Department of Pediatric Oncology and Hematology, Besançon University Hospital, 25000 Besançon, France.
- Département D'oncologie Médicale, Chirurgie et Radiothérapie, Centre Georges-François Leclerc, Unicancer, Université Bourgogne Europe, 21000 Dijon, France.
- Department of Medical Oncology, Poitiers University Hospital, 86000 Poitiers, France.
ORCID-Profile: Clément Bolognini, Fabien Calcagno, Sylvain Causeret, Guillaume Meynard, Loïc Chaigneau
Zitieren
APA
Bolognini, C., Falcoz, A., Simon, P., Calcagno, F., Hervieu, A., Isambert, N., Desmoulins, I., Causeret, S., Thibouw, D., Kalbacher, E., Meynard, G., Vernerey, D., & Chaigneau, L. (2026). Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study. Cancers, 18(21), 3497. https://doi.org/10.3390/cancers18213497
Vancouver
Bolognini C, Falcoz A, Simon P, Calcagno F, Hervieu A, Isambert N, et al. Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study. Cancers. 2026;18(21):3497. doi:10.3390/cancers18213497
BibTeX
@article{Bolognini2026,
author = {Bolognini, Clément and Falcoz, Antoine and Simon, Pauline and Calcagno, Fabien and Hervieu, Alice and Isambert, Nicolas and Desmoulins, Isabelle and Causeret, Sylvain and Thibouw, David and Kalbacher, Elsa and Meynard, Guillaume and Vernerey, Dewi and Chaigneau, Loïc},
title = {Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3497},
doi = {10.3390/cancers18213497}
}
EUVIMED